Characteristics and Risk Factors for Primary Hepatocellular Carcinoma
Abstract
Background: Primary hepatocellular carcinoma (HCC) is the most common liver malignancy.
Aim:To identify the clinical characteristics of patients with HCC and the factors for its occurrence.
Methods: A total of 110 hospitalized patients with HCC was investigated. Histological diagnosis of underlying liver disease was done in 93 patients. Biochemical and hematological parameters were obtained by routine biochemical and hematological techniques. Serum markers for hepatitis B and C viruses and autoantibodies were determined.
SPSS version 17.0 was used for statistical analyses and p<0.05 was considered significant.
Results: Patients were aged from 48 to 82 years (65,8 ± 7). Males dominated (74 pts). Solitary HCC pattern was observed in 87 patients. Viral etiology was proven in 61 patients while alcoholic liver disease was detected in 21 patients. Increased AFP values (? 20 ng/ml) were obtained in 88 pts; values ?200 ng/ml in 71 pts, and values ?400 ng/ml in 57 pts. The clinical presentation was dominated by fatigue, gynecomastia, and bone aches. The most common comorbidities were diabetes mellitus type 2 (53 pts), chronic cardiomyopathy/arterial hypertension (48 pts), and obesity (29 pts).
Comparison of patients with and without cirrhosis (66/110) showed no difference in age, gender, tumor pattern, and AFP values ?20 ng/ml. Those from the first group had higher AFP, larger solitary tumors, greater liver damage and more pronounced clinical symptoms.
Conclusions: HCC is mostly detected in liver cirrhosis. Other risk factors include hepatitis B and C viruses, heavy alcohol abuse, older age, male gender, metabolic and chronic cardiovascular diseases.
Keywords
References
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-E386. https// doi: 10.1002/ijc.29210.
El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-73. https// doi: 10.1053/j.gastro.2011.12.06.
Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int 2016;36:317-24. https// doi: 10.1111/liv.13031.
Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients. Hepatology. 2006;43:1303-10. https// doi: 10.1002/hep.21176.
Wörns MA, Bosslet T, Victor A, et al.. Prognostic factors and outcomes of patients with hepatocellular carcinoma in non-cirrhotic liver. Scand J Gastroenterol 2012;47:718–28. https// doi: 10.3109/00365521.2012.677952.
Giannini EG, Marenco S, Bruzzone L, et al..Hepatocellular carcinoma in patients without cirrhosis in Italy. Dig Liver Dis 2013;45:164–9. https// doi:10.1016/j.dld.2012.08.018.
Mathurin P, Bataller R. Trends in the management and burden of alcoholic liver disease. J Hepatol 2015;62:S38-46. https// doi: 10.1016/j.jhep.2015.03.006.
N'Kontchou G, Paries J, Htar MTT, et al. Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis. Clin Gastroenterol Hepatol 2006;4:1062-8. https// doi: 10.1016/j.cgh.2006.05.013.
Ozakyol A. Global epidemiology of hepatocellular carcinoma (HCC epidemiology). J Gastrointest Cancer 2017;48:238-40. https// doi: 10.1007/s12029-017-9959-0.
Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level. JAMA Oncol 2017;31:1683-91. https// doi:10.1001/jamaoncol.2017.3055.
Akkiz H, Carr BI, Yalc?n KK, et al. Characteristics of hepatocellularcarcinoma aggressiveness factors in Turkish patients. Oncology 2018;94:116-24. https// doi: 10.1159/000484564. Epub 2017 Dec 6.
Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384–91. https// doi: 10.1016/j.jhep.2011.10.027.
Wong W-S V, Jeffrey V. Lazarus JV. Prognosis of MAFLD vs. NAFLD and implications for a nomenclature change. J Hepatol 2021;75:1267-70. https// doi: 10.1016/j.jhep.2021.08.020.
Schrenk D, Bignami M, Bodin L, et al. Risk assessment of aflatoxins in food. EFSA J 2020: eCollection 2020 Mar. https// doi: 10.2903/j.efsa.2020.6040.
Caldwell S. Cryptogenic cirrhosis: what are we missing? Curr Gastroenterol Rep. 2010;12:40-8. https// doi: 10.1007/s11894-009-0082-7.
Mercado-Irizarry A, Torres EA. Cryptogenic cirrhosis: Current knowledge and future directions. Clin Liver Dis 2016;7:69-72. https// doi: 10.1002/cld.539.
Ladenheim MR, Nathan G Kim NG, et al. Sex differences in disease presentation, treatment and clinical outcomes of patients with hepatocellular carcinoma: a single-centre cohort study. BMJ Open Gastroenterl 2016;3:e000107. https// doi: 10.1136/bmjgast-2016-000107.
Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol 2011;9:161-7. https// doi:10.1016/j.cgh.2010.09.017.
European Association for the Study of the Liver. EASL Clinical practice guidelines: Managementof hepatocellular carcinoma. J Hepatol 2012;56:908-43. https// doi: 10.1016/j.jhep.2011.12.001
Sterling RK, Wright EC, Morgan TR, et al. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012;107:64-74. https// doi: 10.1159/000346743.
Zakhary NI, Khodeer SM, Shafik HE, et al. Impact of PIVKA-II in diagnosis of hepatocellular carcinoma. J Adv Res 2013;4:539-46. https// doi: 10.1016/j.jare.2012.10.004.
Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J Vasc Interv Radiol 2002;13:S169-71. https// doi:10.1016/s1051-0443(07)61783-7.
Pinzani M , Rosselli M, Michele Zuckermann M. Liver cirrhosis. Best Pract Res Clin (Review) Gastroenterol 2011;25:281-90. https// doi: 10.1016/j.bpg.2011.02.009.
Pellegrini JR, Munshi R, Patel P, et al. The Impact of Hepatic Cirrhosis on Chronic Obstructive Pulmonary Disease in the United States: A Nationwide Analysis. Cureus 13(7): e16368. https// doi: 10.7759/cureus.16368.
Johnson ME, Fisher DG, Fenaughty A, et al. Hepatitis C virus and depression in drug users. Am J Gastroenterol 1998;93:785-9. https// doi:10.1111/j.1572-0241.1998.225_a.x.93:785–9.
Kanazir M, Boricic I, Delic D, et al. Risk factors for hepatocellular carcinoma: a case-control study in Belgrade (Serbia). Tumori 2010,96:911-7. https// doi: 10.1177/548.6508.
Desai A, Sandhu S, Lai JP, et al. Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review. World J Hepatol 2019;11:1-18. https// doi: 10.4254/wjh.v11.i1.1.
Marchesini G, Moscatiello S, Di Domizio S, et al. Obesity-Associated Liver Disease. J Clin Endocrinol Metab 2008;93:S74-80. https// doi: 10.1210/jc.2008-1399.93:S74 –80.
Schütte K, Schulz C, Poranzke J, et al. Characterization and prognosis of patients with hepatocellular carcinoma (HCC) in the non-cirrhotic liver. BMC Gastroenterology 2014;14:117-27. https// doi: 10.1186/1471-230X-14-117.
Zhang B, Wu Z-Y. Estrogen derivatives: novel therapeutic agents for liver cirrhosis and portal hypertension. Eur J Gastroenterol Hepatol 2013;25:263-70. https// doi: 10.1097/MEG.0b013e32835ab5dc.
DOI: 10.5457/ams.v54i2.753
